Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2012
09/13/2012US20120231082 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
09/13/2012US20120231079 Methods and compositions for controlled delivery of phytochemical agents
09/13/2012US20120231066 Multi-drug liposomes to treat tumors
09/13/2012US20120231053 Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
09/13/2012US20120231050 Synthetic Lactone Formulations and Method of Use
09/13/2012US20120231047 Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
09/13/2012US20120231037 Crystalline drug-containing coatings
09/13/2012US20120231035 Method for inducing cell lysis with immunogenic portions of ny-eso-1 protein
09/13/2012US20120231030 Multi-epitopic vaccine
09/13/2012US20120231026 Methods and compositions for tumor vaccination and therapy
09/13/2012US20120231024 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen as diagnostic and therapeutic tools for prostate cancer
09/13/2012US20120231023 Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
09/13/2012US20120231021 Antibodies specifically binding to the epidermal growth factor receptor
09/13/2012US20120231020 Markers for selecting personalized therapies for the treatment of cancer
09/13/2012US20120231010 Vinpocetine and eburn amonine derivatives for promoting bone growth
09/13/2012US20120231007 Modulators of cell cycle progression
09/13/2012US20120231006 Anti-orai1 antigen binding proteins and uses thereof
09/13/2012US20120231004 Antibodies
09/13/2012US20120231002 Treatment of vasculoproliferative conditions
09/13/2012US20120231001 Preventives/remedies for cancer
09/13/2012US20120230995 Polyspecific binding molecules and uses thereof
09/13/2012US20120230994 Bladder cancer specific ligand peptides
09/13/2012US20120230993 Axl tyrosine kinase inhibitors and methods of making and using the same
09/13/2012US20120230991 Methods and compounds for enhancing anti-cancer therapy
09/13/2012US20120230989 Methods and materials for treating renal cell carcinoma
09/13/2012US20120230988 Antibody targeting osteoclast-related protein siglec-15
09/13/2012US20120230987 Methods for treating conditions associated with c-fms
09/13/2012US20120230983 Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
09/13/2012US20120230972 Salinosporamides and Methods for Use Thereof
09/13/2012US20120230958 Oncolytic vaccinia virus combination cancer therapy
09/13/2012US20120230954 Drug Comprising As The Active Ingredient Proliferative Vector Containing Survivin Promoter
09/13/2012US20120230948 Brachyury polypeptides and methods for use
09/13/2012US20120230947 Biologically active proteins having increased in vivo and/or in vitro stability
09/13/2012US20120230941 Methods for treating nervous system injury and disease
09/13/2012US20120230939 Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
09/13/2012US20120230937 Implantable bio-resorbable polymer
09/13/2012US20120230917 Compositions that include a hydrophobic compound and a polyamino acid conjugate
09/13/2012US20120230911 Tnf-alpha binding proteins
09/13/2012CA2829421A1 Amatoxin-conjugates with improved linkages
09/13/2012CA2829322A1 Androgen receptor antagonists and uses thereof
09/13/2012CA2829287A1 Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
09/13/2012CA2829217A1 Compounds and methods of use in ablative radiotherapy
09/13/2012CA2829188A1 Dispiropyrrolidine derivatives
09/13/2012CA2829082A1 Heterocyclic modulators of lipid synthesis
09/13/2012CA2828940A1 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
09/13/2012CA2827759A1 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
09/12/2012EP2497783A2 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
09/12/2012EP2497772A1 Compound for inhibiting mitotic progression
09/12/2012EP2497501A2 Radionuclides for medical use
09/12/2012EP2497499A1 Amatoxin-conjugates with improved linkages
09/12/2012EP2497497A1 Improved adjuvant therapy of G250-expressing tumors
09/12/2012EP2497483A1 Compositions for treatment and prevention of diabetic complications using osteomeles schwerinae
09/12/2012EP2497471A2 Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
09/12/2012EP2496607A2 Vault complexes for cytokine delivery
09/12/2012EP2496605A1 Ror1 as therapeutic and diagnostic target
09/12/2012EP2496584A1 Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
09/12/2012EP2496582A1 Benzodiazepine bromodomain inhibitor
09/12/2012EP2496581A1 Condensed azepine derivatives as bromodomain inhibitors
09/12/2012EP2496580A1 Benzodiazepine bromodomain inhibitor
09/12/2012EP2496577A1 Imidazopyridine derivatives
09/12/2012EP2496576A1 Imidazo [4, 5-c]quinoline derivates as bromodomain inhibitors
09/12/2012EP2496575A1 Heterocyclic sulfonamide derivatives useful as mek inhibitors
09/12/2012EP2496574A1 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
09/12/2012EP2496567A2 Novel benzopyran kinase modulators
09/12/2012EP2496566A1 Akt / pkb inhibitors
09/12/2012EP2496558A1 Thetrahydroquinolines derivatives as bromodomain inhibitors
09/12/2012EP2496557A1 Tetrahydroquinoline derivatives and their pharmaceutical use
09/12/2012EP2496266A1 Synhetic immunogenic glycoconjugate for melanoma immunotherapy
09/12/2012EP2496257A1 Treatment of cancer involving mutated kras or braf genes
09/12/2012EP2496256A2 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
09/12/2012EP2496245A2 Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
09/12/2012EP2496244A2 Drug resistant immunotherapy for treatment of a cancer
09/12/2012EP2496237A2 Enzyme inhibiting compounds
09/12/2012EP2496234A1 Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
09/12/2012EP2496229A1 Pharmaceuticals containing choline
09/12/2012EP2496225A1 Sphingosine type 1 inhibitors and methods for making and using same
09/12/2012EP2496081A1 Ite for cancer intervention and eradication
09/12/2012CN1883484B Novel pharmacological use of cucurbitacine
09/12/2012CN102666585A Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
09/12/2012CN102666545A Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
09/12/2012CN102666544A Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds
09/12/2012CN102666542A Pyrazolopyrimidine derivatives
09/12/2012CN102666538A Pyrrolopyridinyl-pyrimidin-2-ylamine derivatives
09/12/2012CN102666536A Novel naphthyridine derivatives and the use thereof as kinase inhibitors
09/12/2012CN102666530A Imatinib dichloroacetate and anti-cancer agent comprising the same
09/12/2012CN102666528A Crystalline CDC7 inhibitor salts
09/12/2012CN102666525A Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
09/12/2012CN102666523A Macrocyclic lactone derivatives for the treatment of cancer
09/12/2012CN102666512A Novel MEK inhibitors, useful in the treatment of diseases
09/12/2012CN102666511A Crystalline methylthioninium chloride hydrates
09/12/2012CN102666510A Process
09/12/2012CN102666509A Thiazole derivatives for treating diseases such as cancer
09/12/2012CN102666504A Compounds as lysophosphatidic acid receptor antagonists
09/12/2012CN102666500A Seven-membered ring compound and pharmaceutical use therefor
09/12/2012CN102666498A RAF inhibitor compounds and methods of use thereof
09/12/2012CN102666489A Sphingosine kinase inhibitors
09/12/2012CN102665769A Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
09/12/2012CN102665767A Bisphosphonate-prodrugs
09/12/2012CN102665756A Method of treatment of philadelphia chromosome positive leukaemia
09/12/2012CN102665727A Anti-cancer agent
1 ... 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 ... 2211